[
    {
        "vaccineId": 31,
        "name": "IXCHIQ®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 23
            }
        ]
    },
    {
        "vaccineId": 32,
        "name": "Adenovirus Type 4",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 13
            }
        ]
    },
    {
        "vaccineId": 33,
        "name": "Type 7 Vaccine, Live, Oral®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 13
            }
        ]
    },
    {
        "vaccineId": 34,
        "name": "BioThrax®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 14
            }
        ]
    },
    {
        "vaccineId": 35,
        "name": "CYFENDUS®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 15
            }
        ]
    },
    {
        "vaccineId": 36,
        "name": "Infanrix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 37,
        "name": "Adacel®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 38,
        "name": "DAPTACEL®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 40,
        "name": "Diphtheria-Tetanus-Pertussis Vaccine Adsorbed®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 43,
        "name": "DTwPHepatitisBHibadsorbed®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 44,
        "name": "DTwPHepatitisBHib®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 47,
        "name": "ComBE Five (Liquid)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 48,
        "name": "ComBE Five (Reconstituted)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 49,
        "name": "Pentabio®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 21
            }
        ]
    },
    {
        "vaccineId": 50,
        "name": "DTwPHib®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 51,
        "name": "KINRIX®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 52,
        "name": "Quadracel®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 53,
        "name": "PEDIARIX®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 54,
        "name": "Vaxelis®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 19
            }
        ]
    },
    {
        "vaccineId": 55,
        "name": "HEXASIIL®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 56,
        "name": "Heberbiovac HB®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 45,
        "name": "Healive®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 10
            }
        ]
    },
    {
        "vaccineId": 60,
        "name": "Heplisav B®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 64
            }
        ]
    },
    {
        "vaccineId": 57,
        "name": "Pentacel®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 58,
        "name": "Hexacima; Hexaxim®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 59,
        "name": "Hexyon®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 61,
        "name": "Ambirix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 62,
        "name": "BEtt®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 63,
        "name": "TETAVAX®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 64,
        "name": "TT vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 21
            }
        ]
    },
    {
        "vaccineId": 65,
        "name": "Tetanus Toxoid Vaccine Adsorbed®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 66,
        "name": "Tetatox®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 24
            }
        ]
    },
    {
        "vaccineId": 67,
        "name": "Tenivac®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 68,
        "name": "Adsorbed DT Vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 21
            }
        ]
    },
    {
        "vaccineId": 69,
        "name": "Diftet®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 24
            }
        ]
    },
    {
        "vaccineId": 70,
        "name": "ADSORBED Td VACCINE®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 21
            }
        ]
    },
    {
        "vaccineId": 71,
        "name": "BE Td®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 72,
        "name": "Diphtheria and Tetanus Vaccine Adsorbed (Paediatric)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 73,
        "name": "Diphtheria and Tetanus Vaccine Adsorbed for Adults and Adolescents®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 74,
        "name": "IMOVAX dT adult®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 75,
        "name": "Engerix-B®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 76,
        "name": "Tetadif®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 24
            }
        ]
    },
    {
        "vaccineId": 77,
        "name": "Fendrix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 78,
        "name": "Havrix; Havrix 720 Junior; Havrix 1440 Adult®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 79,
        "name": "Twinrix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 80,
        "name": "Euvax B®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 18
            }
        ]
    },
    {
        "vaccineId": 81,
        "name": "DTP Vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 21
            }
        ]
    },
    {
        "vaccineId": 82,
        "name": "TRIPVAC®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 83,
        "name": "HBVaxPro®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 84,
        "name": "Recombivax HB®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 85,
        "name": "VAQTA®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 86,
        "name": "Eupenta®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 18
            }
        ]
    },
    {
        "vaccineId": 87,
        "name": "Hepatitis B vaccine (rDNA)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 88,
        "name": "PreHevbri; PreHevbrio®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 32
            }
        ]
    },
    {
        "vaccineId": 101,
        "name": "TDVAX®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 26
            }
        ]
    },
    {
        "vaccineId": 113,
        "name": "Boostrix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 120,
        "name": "Easyfive TT®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 20
            }
        ]
    },
    {
        "vaccineId": 131,
        "name": "Infanrix Hexa®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 135,
        "name": "Dengvaxia®",
        "pathogenId": [
            30
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ],
        "licensingDates": [
            {
                "name": "EMA",
                "type": "Approval",
                "date": "18/12/2018",
                "source": "https://docs.google.com/presentation/d/1wVeDY40TY1c2HTit7KpCc8yFCA4MGSe9/edit#slide=id.p1"
            },
            {
                "name": "FDA",
                "type": "Approval",
                "date": "01/05/2019",
                "source": "https://docs.google.com/presentation/d/1wVeDY40TY1c2HTit7KpCc8yFCA4MGSe9/edit#slide=id.p2"
            },
            {
                "name": "WHO",
                "type": "Approval",
                "date": "25/03/2020",
                "source": "https://docs.google.com/presentation/d/1wVeDY40TY1c2HTit7KpCc8yFCA4MGSe9/edit#slide=id.p3"
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Dengvaxia® (MAH: Sanofi)",
                "composition": "Chimeric Yellow Fever Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 3 years",
                "strainCoverage": "Dengue virus, all 4 virus serotypes.",
                "indication": "Dengue prevention against all 4 serotypes in individuals 6-45 years of age with test-confirmed previous dengue infection. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; immunocompromised patients*; pregnancy; breastfeeding ",
                "dosing": "3 S.C. (e.g. in the deltoid region) doses (0.5 mL each); 6-month intervals.",
                "immunogenicity": "Higher antibody responses in adults versus children after 3 doses.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "Pooled VEy vs. symptomatic VCD, children 6-16 years: 62-64% x 25 mo f/u; seropositives: 79.7 – 79.9%VEy-bridging to adults: Immunogenicity after 3 doses is higher in adults than in children, no VEy data.",
                "durationOfProtection": "VEy in year 5 and 6: 14% in subjects 6-16 years with previous DV-infection.",
                "coAdministration": "Before the use of IgG: 6 wk.- 3 mo. waiting period; TdaP with Dengvaxia first dose: equal responses vs. sequential dosing; only descriptive data with bivalent HPV (similar GMTs co-ad vs sequential) and quadrivalent HPV (ratios in GMT from 0.8 to 1 for co-ad vs sequential) vaccines.",
                "reactogenicity": "Headache (51%), pain (49%), malaise (41%), myalgia (41%), asthenia (32%), fever (14%) – independent of serostatus prior to vaccination.",
                "safety": "Increased risk of severe Dengue in not-previously DV-infected subjects, mainly 3 years after 1st dose.",
                "vaccinationGoal": "Individual protection",
                "others": "No notes."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Dengvaxia® (MAH: Sanofi)",
                "composition": "Chimeric Yellow Fever Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 3 years",
                "strainCoverage": "Dengue virus, all 4 virus serotypes.",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals 6 to 16 years of age with test-confirmed previous dengue infection and living in endemic areas. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity, immunocompromised patients*.",
                "dosing": "3 S.C. (e.g. in the deltoid region) doses (0.5 mL each); 6-month intervals.",
                "immunogenicity": "No data are available.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy against VCD (dengue with acute febrile illness (temperature ≥38°C on at least 2 consecutive days) confirmed by dengue RT-PCR (any serotype) and/or dengue non-structural protein 1 (NS1) ELISA Antigen Test) after 3 doses x 12 mo. f/u, 9-16 years: 80.6 % (CI 95% = 50.7, 93.2); 6-14 years: 79.5 % (CI 95% = 44.2, 93.5)",
                "durationOfProtection": "No data are available.",
                "coAdministration": "tuberculin PPD testing: before vaccination or at least 1 month following vaccination.",
                "reactogenicity": "9-16 years: headache (40%), injection site pain (32%), malaise (25%), weakness (25%), myalgia (29%); 6-8 years: headache (27%), injection site pain (28%), malaise (19%), weakness (13%), and myalgia (15%).",
                "safety": "Increased risk of severe Dengue in not-previously DV-infected subjects.",
                "vaccinationGoal": "Individual protection",
                "others": "Safety and effectiveness in the geriatric population (65 years of age and older), pregnant women, and breastfeeding have not been established."
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Dengvaxia® (MAH: Sanofi)",
                "composition": "Chimeric Yellow Fever Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 3 years",
                "strainCoverage": "Dengue virus, all 4 virus serotypes.",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals 6 to 45 years of age with test-confirmed previous dengue infection. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity, immunocompromised patients; pregnancy; breastfeeding.",
                "dosing": "3 S.C. (e.g. in the deltoid region) doses (0.5 mL each); 6-month intervals.",
                "immunogenicity": "Higher antibody responses in adults versus children.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "Pooled VEy vs. symptomatic VCD, children 6-16 years: 62-64% x 25 mo f/u; seropositives: 79.7 – 79.9% VEy-bridging to adults: Immunogenicity after 3 doses is higher in adults than in children, no VEy data.",
                "durationOfProtection": "VEy in year 5 and 6: 14% in subjects 6-16 years with previous DV-infection.",
                "coAdministration": "Before the use of IgG: 6 wk- 3 mo waiting period; can be co-administer with Tdap and HPV vaccines.",
                "reactogenicity": "Very common (1 in 10 people): Headache, myalgia, malaise, myalgia, weakness, fever, erythema.",
                "safety": "Increased risk of severe Dengue in not-previously DV-infected subjects, mainly 3 years after 1st dose.",
                "vaccinationGoal": "Individual protection",
                "others": "Vaccination is not recommended for travelers who have never lived in an endemic area."
            }
        ]
    },
    {
        "vaccineId": 136,
        "name": "Qdenga®",
        "pathogenId": [
            30
        ],
        "manufacturers": [
            {
                "manufacturerId": 28
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Qdenga® (MAH: Takeda)",
                "composition": "Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 18 months",
                "strainCoverage": "Dengue tetravalent (all 4 virus serotypes) vaccine",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals > 4 years of age. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; acute febrile illness; immunosuppressed individuals*; pregnancy; breastfeeding.",
                "dosing": "Two S.C. doses (0.5 mL each) e.g. in the deltoid region; 3-month intervals.",
                "immunogenicity": "In the absence of correlates of protection for dengue, the clinical relevance of immunogenicity data remains to be fully understood.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy in preventing VCD fever in children 4-16 years: 80.2% (CI 95% = 73.3, 85.3); VEy in preventing hospitalizations due to VCD fever: 90.4 (CI 95% =  82.6, 94.7.",
                "durationOfProtection": "VEy in preventing VCD fever and hospitalizations in children 4-16 years 4.5 years after vaccination: 84.1% (CI 95% = 77.8, 88.6).",
                "coAdministration": "Before use of IgG: 6 wk. - 3 mo. waiting period; can be administered with HepA vaccine (adults) or yellow fever vaccine.",
                "reactogenicity": "Injection site pain (50%), headache (35%), myalgia (31%), injection site erythema (27%), malaise (24%), weakness (20%) and fever (11%).",
                "safety": "Transient vaccine viremia was observed after 1st dose in 49% of study participants never infected and in 16% of study participants who had been previously infected. Vaccine viraemia was rarely detected after the second dose. ",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "Safety and efficacy of Qdenga in <4 years not yet established; no data on the use >60 years; limited data in patients with chronic medical conditions; no clinical efficacy study available in subjects >17 years of age, clinical efficacy for >17 years has been inferred from the clinical efficacy in 4-16 years."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Qdenga® (MAH:Takeda)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Qdenga® (MAH:Takeda)",
                "composition": "Dengue Virus serotypes 1,2,3,4 (live, attenuated); produced in Vero cells, recombinant DNA technology (GMO); storage: 2-8°C; shelf life: 18 months",
                "strainCoverage": "Dengue tetravalent (all 4 virus serotypes) vaccine",
                "indication": "Dengue prevention (against all 4 serotypes) in individuals > 6 years of age. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; acute febrile illness; immunosuppressed individuals*; pregnancy; breastfeeding.",
                "dosing": "Two S.C. doses (0.5 mL each) e.g. in the deltoid region; 3-month intervals.",
                "immunogenicity": "In the absence of correlates of protection for dengue, the clinical relevance of immunogenicity data remains to be fully understood.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy in preventing VCD fever in children 4-16 years: 80.2% (CI 95% = 73.3, 85.3); VEy in preventing hospitalizations due to VCD fever: 90.4 (CI 95% =  82.6, 94.7)",
                "durationOfProtection": "VEy in preventing VCD fever and hospitalizations in children 4-16 years 4.5 years after vaccination: 84.1% (CI 95% = 77.8, 88.6).",
                "coAdministration": "Before use of IgG: 6 wk. - 3 mo. waiting period; can be administered with HepA vaccine (adults) or yellow fever vaccine.",
                "reactogenicity": "Very common (>10%): injection site pain or redness, headache, muscle pain, generally feeling unwell, weakness, infections of the nose or throat, fever.",
                "safety": "Transient vaccine viremia was observed after 1st dose in 49% of study participants never infected and in 16% of study participants who had been previously infected. Vaccine viraemia was rarely detected after the second dose. ",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No data in adults above 60 years of age."
            }
        ]
    },
    {
        "vaccineId": 137,
        "name": "Ervebo®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 19
            }
        ]
    },
    {
        "vaccineId": 138,
        "name": "Zabdeno+Mvabea®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 2
            }
        ]
    },
    {
        "vaccineId": 139,
        "name": "ActHIB; Act-HIB®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 140,
        "name": "Haemophilus influenzae type b Conjugate Vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 142,
        "name": "HIBERIX®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 143,
        "name": "Liquid PedvaxHIB®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 144,
        "name": "Quimi Hib®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 159,
        "name": "Gardasil 9®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 160,
        "name": "Cecolin®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 33
            }
        ]
    },
    {
        "vaccineId": 161,
        "name": "Cervarix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "name": "Abrysvo®",
        "vaccineId": 1,
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ],
        "licensers": [
            {
                "licenserId": 1,
                "link": "https://www.fda.gov/media/168889/download?attachment"
            },
            {
                "licenserId": 2,
                "link": "https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_en.pdf"
            }
        ],
        "licensingDates": [
            {
                "name": "EMA",
                "type": "Approval",
                "date": "15/09/2023",
                "source": "https://docs.google.com/presentation/d/12YarRyDG37tD5lL1nYr3MgtyXg3LPqUp/edit#slide=id.p1"
            },
            {
                "name": "FDA",
                "type": "Approval",
                "date": "31/05/2023",
                "source": "https://docs.google.com/presentation/d/12YarRyDG37tD5lL1nYr3MgtyXg3LPqUp/edit#slide=id.p3"
            }
        ],
        "approvalDate": "2023",
        "description": "Abrysvo™ is a vaccine developed by Pfizer to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in certain populations.",
        "introduction": {
            "General Information": {
                "Map Vaccine Preventable Diseases": "Map by disease",
                "Vaccine SmPCs (FDA, EMA, WHO, others)": "Search by disease, include combos",
                "Product profiles": "Pfizer's Abrysvo is approved for two key populations: pregnant individuals (for protecting infants) and older adults.",
                "Pipeline products - summary table": "Phase 3 studies ongoing, showing strong safety and immunogenicity data.",
                "Failed products": "None known."
            },
            "Company products, pipeline": {
                "VPD-BoD, Product presentations, Monograph": "Available as injection.",
                "Pivotal publications / data vaccines": "Published Phase 3 trials showing positive safety and efficacy results.",
                "Interviews": "Interviews with leading researchers discussing vaccine progress and approvals.",
                "Relevant literature": "Scientific articles on RSV vaccines and Abrysvo’s maternal immunization strategy.",
                "Pipeline products - detailed information (TPP)": "Phase 3 trials for additional age groups."
            }
        },
        "productProfiles": [
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Abrysvo® (MAH: Pfizer)",
                "composition": "1 dose (0.5mL) contains RSV stabilized prefusion F proteins (60 µg RSV preF A and 60 µg RSV preF B); produced in Chinese hamster ovary cells by rDNA technology; storage: 2 - 8°C / 8-30°C; shelf life: 3 years / 5 days.",
                "strainCoverage": "RSV subtypes A and B.",
                "indication": "Active immunization of lower respiratory tract disease caused by RSV in individuals ≥ 60 years and pregnant individuals at 32-36 weeks gestational age for the prevention of LRTI/severe LRTI caused by RSV in infants ≤6 mo. of age. To be used based on official recommendations.",
                "dosing": "Single 0.5 mL dose; I.M.",
                "immunogenicity": "No immunogenicity data available in the label.",
                "contraindication": "",
                "efficacyEndpointsPhase3": "No immunogenicity data available in the label.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy in infants born to pregnant individuals: against severe MA RSV LRTI: 81.8%(95%CI: 40.6; 96.3), 90 days after birth; 73.9%(95%CI: 45.6; 88.8), 120 days after birth; 70.9%(95%CI: 44.5; 85.9), 150 days after birth; 69.4%(95%CI: 44.3; 84.1), 180 days after birth; against MA RSV LRTI: 57.1%(95%CI: 14.7; 79.8), 90 days after birth; 56.8%(95%CI: 31.2; 73.5), 120 days after birth; 52.5%(95%CI: 28.7; 68.9), 150 days after birth; 51.3%(95%CI: 29.4; 66.8), 180 days after birth; against RSV-hospitalization: 67.7%(95%CI: 15.9; 89.5), 90 days after birth; 59.5%(95%CI: 8.3; 83.7), 120 days after birth; 56.4%(95%CI: 5.2; 81.5), 150 days after birth; 56.8%(95%CI: 10.1; 80.7), 180 days after birth VEy in individuals ≥ 60: against LRTD with ≥2 symptoms*: 66.7%(95%CI: 28.8; 85.8), 7 mo. f/u; against LRTD with ≥3 symptoms*: 85.7%(95%CI: 32.0; 98.7),7 mo. f/u.",
                "durationOfProtection": "Unknown",
                "coAdministration": "Can be co-administered with Tdap in non-pregnant women (lower GMC to the acellular pertussis antigens was reported; no data in pregnant women).",
                "reactogenicity": "Pregnant women: injection site pain (40.6%), headache (31.0%), muscle pain (26.5%), nausea (20.0%). \n ≥ 60 yrs.: fatigue (15.5%), headache (12.8%), injection site pain (10.5%), muscle pain (10.1%).",
                "safety": "Potential risk of preterm birth before 32 weeks of gestation; higher incidence of atrial fibrillation in vaccinated group and higher incidence of low birth weight and neonatal jaundice in infants of vaccinated mothers in comparison with control group; higher incidence of pre-eclampsia and gestational hypertension in comparison with control group; Miller Fisher Syndrome was reported 8 days after vaccination; Guillain-Barre Syndrome was reported 7 days after vaccination.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "no safety/effectiveness data in non-pregnant individuals <18 yrs.; no data in pregnancy before 24 weeks of gestation and those at increased risk for preterm birth; no safety/effectiveness data for preventing RSV LRTD and severe RSV LRTD in infants born to individuals vaccinated at ≤10 yrs. of age."
            },
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Abrysvo® (MAH: Pfizer)",
                "composition": "1 dose (0.5mL) RSV stabilized pre-F proteins (60 µg RSV preF A and 60 µg RSV preF B); produced in CHO cells by rDNA technology; storage: 2 - 8°C / 8-30°C; shelf life: 3 years/5 days.",
                "strainCoverage": "RSV subtypes A and B.",
                "indication": "Active immunization against RSV-LRTI caused by RSV in individuals ≥ 60 years and passive protection against LRTI caused by RSV in infants ≤6 mo. of age following maternal immunization during pregnancy. To be used based on official recommendations.",
                "contraindication": "Hypersensitivity; acute febrile illness; caution in coagulation disorder.",
                "dosing": "Single dose (0.5mL); I.M.; pregnant women: between weeks 24 and 36 of gestation.",
                "immunogenicity": "No immunogenicity data available in the label.",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "VEy in infants born to pregnant individuals: against severe MA RSV LRTI: 81.8% (95%CI: 40.6; 96.3), 90 days after birth; 73.9% (95%CI: 45.6; 88.8), 120 days after birth; 70.9% (95%CI: 44.5; 85.9), 150 days after birth; 69.4% (95%CI: 44.3; 84.1), 180 days after birth; against MA RSV LRTI: 57.1% (95%CI: 14.7; 79.8), 90 days after birth; 56.8% (95%CI: 31.2; 73.5), 120 days after birth; 52.5% (95%CI: 28.7; 68.9), 150 days after birth; 51.3% (95%CI: 29.4; 66.8), 180 days after birth; VEy in individuals ≥ 60: against LRTD with ≥2 symptoms*: 65.1% (95%CI: 35.9; 82.0); against LRTD with ≥3 symptoms*: 88.9% (95%CI: 53.6; 98.7).",
                "durationOfProtection": "Unknown.",
                "coAdministration": "Can be co-administered with seasonal quadrivalent influenza vaccine; a minimum interval of 2 weeks with a Tdap vaccine (lower immune responses to the pertussis components in co-administration).",
                "reactogenicity": "Pregnant women: injection site pain (41%), headache (31%) ,and myalgia (27%); ≥ 60 years: injection site pain (11%). ",
                "safety": "No safety signal to date.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "no safety/efficacy data in <18yrs; no efficacy/safety data in immunocompromised individuals; no data in pregnancy before 24 weeks of gestation; no safety concerns in co-administration with Tdap in healthy non-pregnant women; no adverse effects in breastfed newborns of vaccinated mothers."
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Abrysvo® (MAH: Pfizer)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy(VEy vs virologically confirmed dengue (VCD))": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ],
        "link": "https://www.pfizer.com/products/product-detail/abrysvotm",
        "lastUpdated": "2024-AUG"
    },
    {
        "vaccineId": 162,
        "name": "Walrinvax®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 34
            }
        ]
    },
    {
        "vaccineId": 163,
        "name": "Gardasil®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 164,
        "name": "Influvac Tetra®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 35
            }
        ]
    },
    {
        "vaccineId": 165,
        "name": "Serinflu®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 35
            }
        ]
    },
    {
        "vaccineId": 166,
        "name": "Fluenz Tetra®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 6
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Fluenz Tetra® (MAH: AstraZeneca)",
                "composition": "1 dose (0.2 mL) contains 107.0±0.5 FFU of each four influenza virus strains (A/Victoria/4897/2022 (H1N1)pdm09-like, A/Darwin/9/2021 (H3N2)-like, B/Phuket/3073/2013-like, and B/Austria/1359417/2021-like); propagated in fertilized hens’ eggs from healthy chicken flocks and produced in Vero cells by reverse genetic technology; storage: 2-8°C; shelf life: 18 weeks.",
                "strainCoverage": "Influenza virus.",
                "indication": "Active immunization for prophylaxis of influenza in individuals 2-17 yrs.; to be used based on official recommendations.",
                "contraindication": "Hypersensitivity; egg protein allergy; immunodeficiency (acute/ chronic leukemias, lymphoma, symptomatic HIV infection, cellular immune deficiencies, high-dose corticosteroids); individuals on salicylate therapy (risk of Reye’s syndrome; avoid using salicylates for 4 weeks after vaccination unless medically indicated); severe asthma or active wheezing (inadequate data); pregnancy; breastfeeding.",
                "dosing": "Nasal; single dose; each dose is 0.2 mL (0.1 mL per nostril); in children with no previous vaccination against seasonal influenza a 2nd dose should be given after an interval of at least 4 weeks.",
                "immunogenicity": "Fluenz Tetra® was non-inferior to Fluenz®.",
                "Efficacy": "Clinical experience with Fluenz® is relevant to Fluenz Tetra® because both vaccines are manufactured using the same process and have overlapping compositions (Vey of Fluenz® during 7 flu seasons: against vaccine strains: 62.2-100%; against all influenza strains: 46.6-93.4%).",
                "durationOfProtection": "Annual revaccination is recommended because immunity declines during the year after vaccination and circulating strains of influenza virus change yearly.",
                "coAdministration": "Can be co-administered with MMR, OPV and varicella vaccines; co-administration with inactivated vaccines has not been studied; avoid administration for 48 hours after the cessation of influenza antiviral therapy; administration of influenza antiviral agents within 2 weeks of vaccination may affect the vaccine response (in case of co-administration, revaccinate based on clinical judgment).",
                "reactogenicity": "Very common: nasal congestion/rhinorrhoea; malaise; decreased appetite; common: pyrexia; myalgia; headache.",
                "safety": "An increased rate of hospitalizations in infants and toddlers 6-11 mo. of age due to GI and respiratory tract infections (occurs more than 6 weeks post-vaccination); an increased rate of wheezing in infants and toddlers 6-23 mo. of age; very rare reports of Guillain-Barré Syndrome and exacerbation of symptoms of Leigh syndrome in the post-marketing setting.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "Avoid using in individuals <24 mo. (increased rates of hospitalization and wheezing); after administering half of the dose in 1 nostril, administer the other half of the dose in the other nostril immediately or shortly thereafter; no need to actively inhale or sniff; not contraindicated in asymptomatic HIV-infected individuals; potential for transmission to close contacts (vaccinees should avoid close contact with severely immunocompromised individuals 1-2 weeks following vaccination), if contact is unavoidable, the potential risk of transmission of the vaccine virus should be weighed against the risk of transmitting wild-type influenza virus; no safety data for children with unrepaired craniofacial malformations."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Fluenz Tetra® (MAH: AstraZeneca)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Fluenz Tetra® (MAH: AstraZeneca)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 167,
        "name": "Fluenz®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 6
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Fluenz® (MAH: AstraZeneca)",
                "composition": "1 dose (0.2 mL) contains 107.0±0.5 FFU of each three influenza virus strains (A/Victoria/4897/2022 (H1N1)pdm09-like, A/Thailand/8/2022 (H3N2) –like, and B/Austria/1359417/2021-like); propagated in fertilized hens’ eggs from healthy chicken flocks and produced in Vero cells by reverse genetic technology; storage: 2-8°C; shelf life: 15 weeks.",
                "strainCoverage": "Influenza virus.",
                "indication": "Active immunization for prophylaxis of influenza in individuals 2-17 yrs.; to be used based on official recommendations.",
                "contraindication": "Hypersensitivity; egg protein allergy; immunodeficiency (acute/ chronic leukemias, lymphoma, symptomatic HIV infection, cellular immune deficiencies, high-dose corticosteroids); individuals on salicylate therapy (risk of Reye’s syndrome; avoid using salicylates for 4 weeks after vaccination unless medically indicated); severe asthma or active wheezing (inadequate data); pregnancy; breastfeeding.",
                "dosing": "Nasal; single dose; each dose is 0.2 mL (0.1 mL per nostril); in children with no previous vaccination against seasonal influenza a 2nd dose should be given after an interval of at least 4 weeks.",
                "immunogenicity": "No data in the label.",
                "Efficacy": "VEy during 7 flu seasons: against vaccine strains: 62.2-100%; against all influenza strains: 46.6-93.4%.",
                "durationOfProtection": "Annual revaccination is recommended because immunity declines during the year after vaccination and circulating strains of influenza virus change yearly.",
                "coAdministration": "Can be co-administered with MMR, OPV and varicella vaccines; co-administration with inactivated vaccines has not been studied; avoid administration for 48 hours after the cessation of influenza antiviral therapy; administration of influenza antiviral agents within 2 weeks of vaccination may affect the vaccine response (in case of co-administration, revaccinate based on clinical judgment).",
                "reactogenicity": "Very common: nasal congestion/rhinorrhoea; malaise; decreased appetite; common: pyrexia; myalgia; headache.",
                "safety": "An increased rate of hospitalizations in infants and toddlers 6-11 mo. of age due to GI and respiratory tract infections (occurs more than 6 weeks post-vaccination); an increased rate of wheezing in infants and toddlers 6-23 mo. of age; very rare reports of Guillain-Barré Syndrome and exacerbation of symptoms of Leigh syndrome in the post-marketing setting.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "Avoid using in individuals <24 mo. (increased rates of hospitalization and wheezing); after administering half of the dose in 1 nostril, administer the other half of the dose in the other nostril immediately or shortly thereafter; no need to actively inhale or sniff; not contraindicated in asymptomatic HIV-infected individuals; potential for transmission to close contacts (vaccinees should avoid close contact with severely immunocompromised individuals 1-2 weeks following vaccination), if contact is unavoidable, the potential risk of transmission of the vaccine virus should be weighed against the risk of transmitting wild-type influenza virus; no safety data for children with unrepaired craniofacial malformations."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Fluenz® (MAH: AstraZeneca)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Fluenz® (MAH: AstraZeneca)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 168,
        "name": "Pandemic Influenza Vaccine H5N1 AstraZeneca®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 6
            }
        ]
    },
    {
        "vaccineId": 169,
        "name": "Influenza Vaccine (Split Virion), Inactivated®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 36
            }
        ]
    },
    {
        "vaccineId": 170,
        "name": "Influenza A(H1N1) 2009 Monovalent (CSL Limited)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 37
            }
        ]
    },
    {
        "vaccineId": 171,
        "name": "GC FLU inj.®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 38
            }
        ]
    },
    {
        "vaccineId": 172,
        "name": "GC FLU Quadrivalent inj.®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 38
            }
        ]
    },
    {
        "vaccineId": 173,
        "name": "Green Flu S®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 38
            }
        ]
    },
    {
        "vaccineId": 174,
        "name": "Adjupanrix®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 175,
        "name": "FLUARIX QUADRIVALENT®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 176,
        "name": "FLUARIX®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 177,
        "name": "Influenza Vaccine (Split virion, inactivated)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 39
            }
        ]
    },
    {
        "vaccineId": 178,
        "name": "Arepanrix®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 40
            }
        ]
    },
    {
        "vaccineId": 179,
        "name": "FluLaval Quadrivalent®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 40
            }
        ]
    },
    {
        "vaccineId": 180,
        "name": "FLULAVAL®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 40
            }
        ]
    },
    {
        "vaccineId": 181,
        "name": "Influenza A (H1N1) 2009 Monovalent (ID Biomedical Corporation of Quebec)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 40
            }
        ]
    },
    {
        "vaccineId": 182,
        "name": "Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 40
            }
        ]
    },
    {
        "vaccineId": 183,
        "name": "IL YANG FLU Vaccine INJ.®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 41
            }
        ]
    },
    {
        "vaccineId": 184,
        "name": "Influenza Trivalent Vaccine (split virion, inactivated)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 42
            }
        ]
    },
    {
        "vaccineId": 185,
        "name": "FluMist Quadrivalent®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 43
            }
        ]
    },
    {
        "vaccineId": 186,
        "name": "FluMist®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 43
            }
        ]
    },
    {
        "vaccineId": 187,
        "name": "Influenza A (H1N1) 2009 Monovalent (MedImmune)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 43
            }
        ]
    },
    {
        "vaccineId": 188,
        "name": "Influenza A (H1N1) 2009 Monovalent (Novartis)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 8
            }
        ]
    },
    {
        "vaccineId": 189,
        "name": "Flublok Quadrivalent®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 44
            }
        ]
    },
    {
        "vaccineId": 190,
        "name": "Flublok®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 44
            }
        ]
    },
    {
        "vaccineId": 191,
        "name": "Fluzone Quadrivalent; Fluzone High-Dose Quadrivalent; Fluzone Intradermal Quadrivalent®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 192,
        "name": "Fluzone; Fluzone High-Dose-®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 193,
        "name": "Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 194,
        "name": "Influenza Virus Vaccine, H5N1®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 195,
        "name": "Panenza®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 196,
        "name": "Supemtek®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 197,
        "name": "Vaxigrip®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 198,
        "name": "VaxigripTetra®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 199,
        "name": "Aflunov®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Aflunov® (MAH: Seqirus)",
                "composition": "1 dose (0.5 mL) contains 7.5µg influenza virus HA (A/turkey/Turkey/1/2005 (H5N1)-like (NIBRG-23) (clade 2.2.1) strain); propagated in fertilized hens’ eggs from healthy chicken flocks; storage: 2-8°C (protect from light); shelf life: 2 years.",
                "strainCoverage": "Influenza virus H5N1.",
                "indication": "Active immunization against H5N1 subtype of Influenza A virus in individuals ≥18 yrs.; to be used based on official recommendations.",
                "contraindication": "Hypersensitivity; egg/chicken protein allergy (in a pandemic situation use with caution); febrile illness until the fever is resolved; use risk/benefit strategy in bleeding disorder; use risk/benefit strategy in pregnancy and breastfeeding.",
                "dosing": "I.M; 2 doses (each 0.5 mL); at least 3 weeks intervals; in the event of a pandemic, a single dose may be administered in previously vaccinated individuals.",
                "immunogenicity": "Seroprotection rate (anti-HA antibody): 6 mo.- 8 yrs.: 86-87% against vaccine strain; 18-60 yrs.: 91% (95% CI: 85; 94) against vaccine strain, 62-83% against heterologous H5N1 strains; ≥61 yrs.: 82% (95% CI: 74; 88) against vaccine strain, 45-61% against heterologous H5N1 strains.",
                "Efficacy": "Data from animal challenge studies in the ferret model; VEy (2 doses): 100% against vaccine strain; 87-92% against heterologous H5N1 strains.",
                "durationOfProtection": "No data in the label.",
                "coAdministration": "May be co-administered with non-adjuvanted seasonal influenza vaccines.",
                "reactogenicity": "Very common: injection site pain, swelling, induration, redness; malaise; chills; fatigue; myalgia; headache; common: arthralgia; nausea; sweating; injection site ecchymosis; fever.",
                "safety": "No safety signals to date.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No safety/efficacy data in <18 yrs.; no data for S.C route of administration; no safety/immunogenicity/efficacy data to support interchangeability with other H5N1 monovalent vaccines."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Aflunov® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Aflunov® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 200,
        "name": "Afluria Quadrivalent®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 201,
        "name": "Afluria®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 202,
        "name": "AUDENZ®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ],
        "productProfiles": [
            {
                "type": "FDA",
                "name": "FDA-Product Profile: AUDENZ® (MAH: Seqirus)",
                "composition": "1 dose (0.5 mL) contains 7.5µg influenza virus HA (A/turkey/Turkey/1/2005 NIBRG-23 strain); propagated in MDCK cells; storage: 2-8°C (protect from light); shelf life: unknown.",
                "strainCoverage": "Influenza A virus H5N1.",
                "indication": "Active immunization to prevent disease caused by the influenza A virus H5N1 subtype in individuals ≥6 mo. at increased risk of exposure to the virus; to be used based on official recommendations.",
                "contraindication": "I.M; 2 doses (each 0.5 mL); 3 weeks apart.",
                "dosing": "Hypersensitivity; use risk/benefit strategy if Guillain-Barré Syndrome has occurred within 6 weeks of previous influenza vaccination; limited data in pregnancy; use risk/benefit strategy in breastfeeding.",
                "immunogenicity": "Seroconversion rate (HI antibody titers): 6 mo.- 17 yrs.: 96% (95% CI: 93; 98); 18-64 yrs.: 79.9% (95% CI: 77.4; 82.3); ≥65 yrs.: 54% (95% CI: 51; 57)",
                "Efficacy": "No data in the label.",
                "durationOfProtection": "No data in the label.",
                "coAdministration": "No data in the label.",
                "reactogenicity": "Very common: 18-64 yrs.: injection site pain (64%); fatigue (25%); headache (25%); malaise (22%); myalgia (14%); arthralgia (10%); nausea (10%); ≥ 65 yrs.: injection site pain (36%); fatigue (20%); malaise (16%); headache (16%); arthralgia (10%); 6 mo.-5 yrs.: injection site tenderness (56%); irritability (30%); sleepiness (25%); change in eating habits (18%); fever (16%); 6-17 yrs.: injection site pain (68%); myalgia (30%); fatigue (27%); malaise (25%); headache (22%); loss of appetite (14%); nausea (13%); arthralgia (13%). ",
                "safety": "An increased risk of GBS was reported.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No safety/effectiveness data in <6 mo.; avoid injection in the gluteal region or areas with a major nerve trunk."
            },
            {
                "type": "EMA",
                "name": "EMA-Product Profile: AUDENZ® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: AUDENZ® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 203,
        "name": "Celldemic®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Celldemic® (MAH: Seqirus)",
                "composition": "1 dose (0.5 mL) contains 7.5µg influenza virus HA (A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1)); propagated in MDCK cells; storage: 2-8°C (protect from light); shelf life: 1 years.",
                "strainCoverage": "Influenza virus H5N1.",
                "indication": "Active immunization against H5N1 subtype of Influenza A virus in individuals ≥6 mo.; to be used based on official recommendations.",
                "contraindication": "Hypersensitivity; acute severe febrile illness or acute infection; caution in bleeding disorder; use risk/benefit strategy in pregnancy; no data in breastfeeding.",
                "dosing": "I.M; 2 doses (each 0.5 mL); 3 weeks interval.",
                "immunogenicity": "Seroconversion rate (HI antibody titers): 6 mo.- 17 yrs.: 96% (95% CI: 93; 98) against vaccine strain, 32-72% against heterologous H5N1 strains; 18-64 yrs.: 79.9% (95% CI: 77.4; 82.3) against vaccine strain, 28-55% against heterologous H5N1 strains; ≥65 yrs.: 54% (95% CI: 51.0; 57.0) against vaccine strain, 17-46% against heterologous H5N1 strains.",
                "Efficacy": "No data in the label.",
                "durationOfProtection": "The duration of protection following the primary vaccination schedule is unknown. A reduction of antibody titres was observed when assessed 6-12 mo. after the primary vaccination series.",
                "coAdministration": "No data in the label.",
                "reactogenicity": "≥18 yrs.: very common: injection site pain; fatigue; malaise; arthralgia; myalgia; headache; common: loss of appetite; nausea; injection site bruising, induration; chills; fever; 6 mo.- 5 yrs.: very common: decreased appetite; injection site pain, tenderness; somnolence; irritability; fever; common: vomiting; diarrhea; injections site induration, erythema; 6-18 yrs.: injection site pain, tenderness; fatigue; malaise; arthralgia; myalgia; decreased appetite; nausea; headache; common: vomiting; diarrhea; injections site induration, erythema; fever.",
                "safety": "Cases of convulsion (with and without fever) were reported during the 2009 pandemic for H1N1 vaccines manufactured with the MF59 adjuvant, specially in paediatric subjects and subjects with a history of epilepsy.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No safety/efficacy data in <6 mo.; no efficacy/safety/ immunogenicity data in immunocompromised individuals; no data for interchangeability with other H5 monovalent vaccines; no established data for the need to booster dose (early waning of the antibody levels observed especially in adults)."
            },
            {
                "type": "FDA",
                "name": "FDA-Product Profile: Celldemic® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Celldemic® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 204,
        "name": "Celtura®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 205,
        "name": "Fluad Tetra; FLUAD QUADRIVALENT®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ],
        "productProfiles": [
            {
                "type": "FDA",
                "name": "FDA-Product Profile: FLUAD QUADRIVALENT® (MAH: Seqirus)",
                "composition": "1 dose (0.5 mL) contains 15µg influenza virus HA (each A/Victoria/4897/2022 (H1N1)pdm09-like strain, A/Darwin/9/2021 (H3N2)-like strain, B/Austria/1359417/2021-like strain, and B/Phuket/3073/2013-like strain); propagated in the allantoic cavity of embryonated hens’ eggs; storage: 2-8°C (protect from light); shelf life: unknown.",
                "strainCoverage": "Influenza virus A (H1N1, H3N2) and B.",
                "indication": "Active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine in individuals ≥65 years; to be used based on official recommendations.",
                "dosing": "I.M; single dose (0.5 mL).",
                "immunogenicity": "Hypersensitivity; egg protein allergy; use risk/benefit strategy if Guillain-Barré Syndrome has occurred within 6 weeks of previous influenza vaccination, ",
                "contraindication": "Seroconversion rate (HI antibody titers): ≥65 yrs.: 78.0% (95% CI: 75.7; 80.2) against A/H1N1, 84.6% (95% CI: 82.5%; 86.5) against A/H3N2, 60.8% (95% CI: 58.1; 63.4) against B/Yamagata, 65.5% (95% CI: 62.9; 68.1) against B/Victoria.",
                "efficacyEndpointsPhase3": "No immunogenicity data available in the label.",
                "Efficacy": "No data in the label.",
                "durationOfProtection": "No data in the label.",
                "coAdministration": "No data in the label.",
                "reactogenicity": "Very common: injection site pain (16.3%); headache (10.8%); fatigue (10.5%).",
                "safety": "GBS was reported.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "No safety/effectiveness data in <6 mo. of age and in children >72 mo. of age."
            },
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Fluad Tetra® (MAH: Seqirus)",
                "composition": "1 dose (0.5 mL) contains 15µg influenza virus HA (each of A/Victoria/4897/2022 (H1N1)pdm09-like, A/Thailand/8/2022 (H3N2)-like, B/Austria/1359417/2021-like, and B/Phuket/3073/2013-like strains); propagated in fertilized hens’ eggs from healthy chicken flocks; storage: 2-8°C (protect from light); shelf life: 1 years.",
                "strainCoverage": "Influenza virus.",
                "indication": "Active immunization for the prophylaxis of influenza in ≥50 yrs.; to be used based on official recommendations.",
                "contraindication": "Hypersensitivity; febrile illness until the fever is resolved; caution in bleeding disorders; pregnancy; breastfeeding.",
                "dosing": "I.M; single dose (0.5 mL).",
                "immunogenicity": "50-64 yrs.: Fluad Tetra elicited higher immune responses compared to a nonadjuvanted quadrivalent comparator influenza vaccine; seroconversion rate (HI antibody titers), ≥65 yrs.: 13.4-39.3% (Fluad Tetra® was non-inferior to comparators (two adjuvanted flu vaccines containing B-Victoria and B-Yamagata strains)).",
                "Efficacy": "No data in the label.",
                "durationOfProtection": "Annual revaccination is recommended because immunity declines during the year after vaccination and circulating strains of influenza virus change yearly..",
                "coAdministration": "No data in the label.",
                "reactogenicity": "Very common: injection site pain; fatigue; myalgia; arthralgia; headache; common: loss of appetite; nausea; diarrhea; injection site ecchymosis, erythema, induration; chills; influenza-like illness; fever (≥38 °C).",
                "safety": "No safety signals to date.",
                "vaccinationGoal": "Individual protection; outbreak control.",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Fluad Tetra®; FLUAD QUADRIVALENT® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 206,
        "name": "FLUAD®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 207,
        "name": "Flucelvax Tetra; Flucelvax Quadrivalent®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 208,
        "name": "Flucelvax®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 209,
        "name": "Fluvirin®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 210,
        "name": "Focetria®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 211,
        "name": "Foclivia®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ],
        "productProfiles": [
            {
                "type": "EMA",
                "name": "EMA-Product Profile: Foclivia® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Fluad Tetra®; FLUAD QUADRIVALENT® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            },
            {
                "type": "WHO",
                "name": "WHO-Product Profile: Fluad Tetra®; FLUAD QUADRIVALENT® (MAH: Seqirus)",
                "composition": "- not licensed yet -",
                "strainCoverage": "- not licensed yet -",
                "indication": "- not licensed yet -",
                "contraindication": "- not licensed yet -",
                "dosing": "- not licensed yet -",
                "immunogenicity": "- not licensed yet -",
                "Efficacy": "- not licensed yet -",
                "durationOfProtection": "- not licensed yet -",
                "coAdministration": "- not licensed yet -",
                "reactogenicity": "- not licensed yet -",
                "safety": "- not licensed yet -",
                "vaccinationGoal": "- not licensed yet -",
                "others": "- not licensed yet -"
            }
        ]
    },
    {
        "vaccineId": 212,
        "name": "Incellipan®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 213,
        "name": "Panvax®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 214,
        "name": "Zoonotic Influenza Vaccine Seqirus®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    },
    {
        "vaccineId": 215,
        "name": "NASOVAC Influenza Vaccine, Live Attenuated (Human) Freeze Dried®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 216,
        "name": "Nasovac-S Influenza Vaccine, Live, Attenuated (Human)®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 217,
        "name": "SKYCellflu inj.®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 46
            }
        ]
    },
    {
        "vaccineId": 218,
        "name": "SKYCellflu Quadrivalent inj.®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 46
            }
        ]
    },
    {
        "vaccineId": 219,
        "name": "JEEV (3µg)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 220,
        "name": "JEEV (6µg)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 221,
        "name": "Japanese Encephalitis Vaccine live (SA14-14-2)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 47
            }
        ]
    },
    {
        "vaccineId": 222,
        "name": "IMOJEV MD®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 48
            }
        ]
    },
    {
        "vaccineId": 223,
        "name": "Ixiaro®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 23
            }
        ]
    },
    {
        "vaccineId": 224,
        "name": "Measles and Rubella Vaccine (Live) (Attenuated, Freeze Dried)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 225,
        "name": "Priorix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 226,
        "name": "M M Rvaxpro; M M R II; rHA M M R II®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 227,
        "name": "ProQuad®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 29
            }
        ]
    },
    {
        "vaccineId": 228,
        "name": "Measles vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 21
            }
        ]
    },
    {
        "vaccineId": 229,
        "name": "Measles and Rubella Vaccine, Live, Attenuated®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 230,
        "name": "Measles Vaccine, Live, Attenuated®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 231,
        "name": "Measles, Mumps and Rubella Vaccine, Live, Attenuated®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 232,
        "name": "MVA BN (Imvanex; JYNNEOS)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 49
            }
        ]
    },
    {
        "vaccineId": 233,
        "name": "ACAM2000®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 15
            }
        ]
    },
    {
        "vaccineId": 234,
        "name": "BCG vaccine AJV®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 51
            }
        ]
    },
    {
        "vaccineId": 235,
        "name": "BCG vaccine (BB-NCIPD)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 24
            }
        ]
    },
    {
        "vaccineId": 236,
        "name": "BCG Freeze Dried Glutamate vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 52
            }
        ]
    },
    {
        "vaccineId": 237,
        "name": "BCG Vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 53
            }
        ]
    },
    {
        "vaccineId": 238,
        "name": "TICE BCG®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 53
            }
        ]
    },
    {
        "vaccineId": 239,
        "name": "BCG vaccine (Serum Institute of India)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 240,
        "name": "Bexsero®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 241,
        "name": "Menveo®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 242,
        "name": "Nimenrix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ]
    },
    {
        "vaccineId": 243,
        "name": "Penbraya®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ]
    },
    {
        "vaccineId": 244,
        "name": "Trumenba®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ]
    },
    {
        "vaccineId": 245,
        "name": "Menactra®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 246,
        "name": "Menquadfi®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 22
            }
        ]
    },
    {
        "vaccineId": 247,
        "name": "MenFive®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 248,
        "name": "Meningococcal A Conjugate 5 micrograms MenAfriVac 5µg®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ]
    },
    {
        "vaccineId": 249,
        "name": "Meningococcal A Conjugate MenAfriVac®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 1
            }
        ]
    },
    {
        "vaccineId": 250,
        "name": "Mosquirix®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 251,
        "name": "CYVAC®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 11
            }
        ]
    },
    {
        "vaccineId": 252,
        "name": "IPV Vaccine AJV®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 51
            }
        ]
    },
    {
        "vaccineId": 253,
        "name": "Picovax®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 51
            }
        ]
    },
    {
        "vaccineId": 254,
        "name": "Poliomyelitis Vaccine (live, oral attenuated, human Diploid Cell), type 1 and 3®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 65
            }
        ]
    },
    {
        "vaccineId": 255,
        "name": "Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (Beijing Institute)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 65
            }
        ]
    },
    {
        "vaccineId": 256,
        "name": "BIOPOLIO B1,3®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 12
            }
        ]
    },
    {
        "vaccineId": 257,
        "name": "BIOPOLIO®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 12
            }
        ]
    },
    {
        "vaccineId": 258,
        "name": "Poliomyelitis vaccine; Poliomyelitis vaccine multidose®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 54
            }
        ]
    },
    {
        "vaccineId": 259,
        "name": "Poliomyelitis Vaccine - Novel Oral (nOPV) Type 2®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 16
            }
        ]
    },
    {
        "vaccineId": 260,
        "name": "Polio Sabin Mono T1®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 261,
        "name": "Polio Sabin Mono Three (oral)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 262,
        "name": "Polio Sabin Mono Two (oral)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 263,
        "name": "Polio Sabin One and Three®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 17
            }
        ]
    },
    {
        "vaccineId": 264,
        "name": "Bivalent type 1&3 Oral Poliomyelitis vaccine, IP (bOPV1&3)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 55
            }
        ]
    },
    {
        "vaccineId": 265,
        "name": "Polioviral vaccine®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 55
            }
        ]
    },
    {
        "vaccineId": 266,
        "name": "Monovalent type 1 Oral Poliomyelitis vaccine, IP (mOPV1)®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 55
            }
        ]
    },
    {
        "vaccineId": 267,
        "name": "Eupolio Inj®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 18
            }
        ]
    },
    {
        "vaccineId": 268,
        "name": "Vaxelis®",
        "pathogenId": [
            6
        ],
        "manufacturers": [
            {
                "manufacturerId": 19
            }
        ]
    },
    {
        "vaccineId": 267,
        "name": "Agriflu®",
        "pathogenId": [
            8
        ],
        "manufacturers": [
            {
                "manufacturerId": 45
            }
        ]
    }
]